Newly Identified Germline Mutations Associated with Prostate Cancer Risk and Aggressiveness
Dr. Brian T. Helfand reviews germline mutations and polygenic risk scores that shape prostate cancer risk, aggressiveness, and treatment decisions.
Read More
Select Page
Brian T. Helfand, MD, PhD, is Chief of the Division of Urology and the Ronald L. Chez Family and Richard Melman Family Endowed Chair at NorthShore University HealthSystem. He is Director of the Personalized Prostate Program and Director of Clinical Research in the Program for Personalized Cancer Care (PPCC). He is also an active surgical scientist who is involved in the care of patients with prostate cancer. His clinical care and research is focused on the implementation of genetic tests and biomarker studies for prostate cancer.
Dr. Helfand completed his undergraduate degree at Emory University. He received his medical training and PhD in Cell and Molecular Biology and Genetics from Northwestern University. He is a fellowship-trained urologic oncologist who has focused his research career on prostate cancer. He was recruited in 2011 from Northwestern University’s Feinberg School of Medicine, where he was faculty in the Department of Urology. Dr. Helfand is an internationally-known urologist and genomic translational researcher. He has received multiple grants from the NIH and has published over 140 peer-reviewed manuscripts in journals such as Nature Genetics, The Journal of Cell Biology, and Science Translational Medicine.
Dr. Helfand is involved in national and international research collaborations as an active member of the International Consortium for Prostate Cancer Genetics (ICPCG), the Prostate Cancer Specialized Program of Research Excellence (SPORE), the IMPACT) study, and the Lower Urinary Tract Dysfunction Research Network (LURN). His current research goals are focused on germline genetic variations and mutations. He is determined to use this information to assist in personal and informed clinical decision making about prostate cancer screening and treatment for patients and their family members.
Brian T. Helfand, MD, PhD | Nov 2025
Dr. Brian T. Helfand reviews germline mutations and polygenic risk scores that shape prostate cancer risk, aggressiveness, and treatment decisions.
Read MoreBrian T. Helfand, MD, PhD | Nov 2025
Brian T. Helfand, MD, PhD, discusses focal therapy in prostate cancer management, emphasizing its potential and challenges.
Read MoreBrian T. Helfand, MD, PhD | Sep 2025
Brian T. Helfand, MD, PhD, addresses genetic and polygenic risk scoring in identifying men at higher risk of developing prostate cancer.
Read MoreLeonard G. Gomella, MD, FACS, and Brian T. Helfand, MD, PhD, discuss genetic testing in prostate cancer risk assessment and management.
Read MoreBrian T. Helfand, MD, PhD | Jun 2025
Brian T. Helfand, MD, PhD, discusses recent advancements in imaging techniques for prostate cancer detection and management.
Read More